Sutro Biopharma (STRO) Total Non-Current Liabilities (2016 - 2026)

Sutro Biopharma has reported Total Non-Current Liabilities for 10 years, with the latest figure at $304.6 million in Q4 2025.

• Quarterly Total Non-Current Liabilities fell 10.65% year-over-year to $304.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $304.6 million (down 10.65% YoY) and the FY2025 annual result came in at $304.6 million, down 10.65% from the prior year.
• Total Non-Current Liabilities climbed to $304.6 million in Q4 2025 per STRO's latest filing, from $295.2 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $345.5 million in Q1 2025 and troughed at $50.6 million in Q1 2021.
• A 5-year average of $222.0 million and a median of $292.8 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities retreated 29.44% in 2021, then surged 242.94% in 2022.
• Over 5 years, Total Non-Current Liabilities stood at $88.7 million in 2021, then soared by 113.96% to $189.8 million in 2022, then jumped by 68.3% to $319.4 million in 2023, then gained by 6.74% to $340.9 million in 2024, then dropped by 10.65% to $304.6 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $304.6 million, $295.2 million, and $292.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.